-transparent.png){kind=logo}
The antihypertensive effect of alprenolol has been studied before, during and after additional pentobarbitone treatment. The combined alprenolol-pentobarbitone treatment significantly decreased alprenolol levels by 59% and 4-hydroxyalprenolol by 24%. The effect was significant after three doses and declined over 4-5 days after pentobarbitone withdrawal. The decreased alprenolol plasma levels were associated with increased pulse rate (6%), and systolic (8%) and diastolic (9%) blood pressure. The inhibition of exercise tachycardia by alprenolol was reduced by 18% at the end of pentobarbitone treatment compared to initial monotherapy with alprenolol. The interaction is probably clinically important in those patients with hypertension and angina pectoris that are treated with barbiturates and alprenolol.
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
January 1976,
Acta medica Scandinavica,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
August 2004,
Therapeutic drug monitoring,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
March 1977,
Harefuah,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
October 1971,
Lakartidningen,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
August 1974,
European journal of clinical pharmacology,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
January 1979,
Acta medica Scandinavica,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
February 1979,
British journal of clinical pharmacology,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
June 2001,
Therapeutic drug monitoring,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
January 1974,
Acta medica Scandinavica. Supplementum,
P Seideman, and
K O Borg, and
K Haglund, and
C Von Bahr
January 1990,
The British veterinary journal,
